Marina K Baine1, Min-Shu Hsieh2, W Victoria Lai3, Jacklynn V Egger3, Achim A Jungbluth1, Yahya Daneshbod4, Amanda Beras1, Rowanne Spencer1, Jessica Lopardo1, Francis Bodd1, Joseph Montecalvo5, Jennifer L Sauter1, Jason C Chang1, Darren J Buonocore1, William D Travis1, Triparna Sen3, John T Poirier6, Charles M Rudin3, Natasha Rekhtman7. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, Loma Linda University School of Medicine, Loma Linda, California. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, Henry Ford Hospital, Detroit, Michigan. 6. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Perlmutter Cancer Center, New York University Langone Health, New York, New York. 7. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rekhtman@mskcc.org.
Abstract
INTRODUCTION: Recent studies have identified subtypes of small cell lung carcinoma (SCLC) defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional regulators. There are only limited data on the distribution of these markers at the protein level and associated pathologic characteristics in clinical SCLC samples. METHODS: The expression of ASCL1, NEUROD1, POU2F3, and YAP1 was analyzed by immunohistochemistry in 174 patient samples with SCLC. Subtypes defined by these markers were correlated with histologic characteristics, expression of classic neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1), and other SCLC markers, including the neuroendocrine phenotype-associated markers TTF-1 and DLL3. RESULTS: ASCL1 and NEUROD1 expression had the following distribution: (1) 41% ASCL1+/NEUROD1-; (2) 37% ASCL1+/NEUROD1+; (3) 8% ASCL1-/NEUROD1+; and (4) 14% ASCL1-/NEUROD1-. On the basis of their relative expression, 69% of cases were ASCL1-dominant and 17% were NEUROD1-dominant. POU2F3 was expressed in 7% of SCLC and was mutually exclusive of ASCL1 and NEUROD1. YAP1 was expressed at low levels, primarily in combined SCLC, and was not exclusive of other subtypes. Both ASCL1-dominant and NEUROD1-dominant subtypes were associated with neuroendocrine markerhigh/TTF-1high/DLL3high profile, whereas POU2F3 and other ASCL1/NEUROD1 double-negative tumors were neuroendocrine markerlow/TTF-1low/DLL3low. CONCLUSIONS: This is the first comprehensive immunohistochemical and histopathologic analysis of novel SCLC subtypes in patient samples. We confirm that ASCL1/NEUROD1 double-negative tumors represent a distinct neuroendocrine-low subtype of SCLC, which is either uniquely associated with POU2F3 or lacks a known dominant regulator. The expression profiles of these markers appear more heterogeneous in native samples than in experimental models, particularly with regard to the high prevalence of ASCL1/NEUROD1 coexpression. These findings may have prognostic and therapeutic implications and warrant further clinical investigation.
INTRODUCTION: Recent studies have identified subtypes of small cell lung carcinoma (SCLC) defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional regulators. There are only limited data on the distribution of these markers at the protein level and associated pathologic characteristics in clinical SCLC samples. METHODS: The expression of ASCL1, NEUROD1, POU2F3, and YAP1 was analyzed by immunohistochemistry in 174 patient samples with SCLC. Subtypes defined by these markers were correlated with histologic characteristics, expression of classic neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1), and other SCLC markers, including the neuroendocrine phenotype-associated markers TTF-1 and DLL3. RESULTS: ASCL1 and NEUROD1 expression had the following distribution: (1) 41% ASCL1+/NEUROD1-; (2) 37% ASCL1+/NEUROD1+; (3) 8% ASCL1-/NEUROD1+; and (4) 14% ASCL1-/NEUROD1-. On the basis of their relative expression, 69% of cases were ASCL1-dominant and 17% were NEUROD1-dominant. POU2F3 was expressed in 7% of SCLC and was mutually exclusive of ASCL1 and NEUROD1. YAP1 was expressed at low levels, primarily in combined SCLC, and was not exclusive of other subtypes. Both ASCL1-dominant and NEUROD1-dominant subtypes were associated with neuroendocrine markerhigh/TTF-1high/DLL3high profile, whereas POU2F3 and other ASCL1/NEUROD1 double-negative tumors were neuroendocrine markerlow/TTF-1low/DLL3low. CONCLUSIONS: This is the first comprehensive immunohistochemical and histopathologic analysis of novel SCLC subtypes in patient samples. We confirm that ASCL1/NEUROD1 double-negative tumors represent a distinct neuroendocrine-low subtype of SCLC, which is either uniquely associated with POU2F3 or lacks a known dominant regulator. The expression profiles of these markers appear more heterogeneous in native samples than in experimental models, particularly with regard to the high prevalence of ASCL1/NEUROD1 coexpression. These findings may have prognostic and therapeutic implications and warrant further clinical investigation.
Authors: François Gerbe; Emmanuelle Sidot; Danielle J Smyth; Makoto Ohmoto; Ichiro Matsumoto; Valérie Dardalhon; Pierre Cesses; Laure Garnier; Marie Pouzolles; Bénédicte Brulin; Marco Bruschi; Yvonne Harcus; Valérie S Zimmermann; Naomi Taylor; Rick M Maizels; Philippe Jay Journal: Nature Date: 2016-01-14 Impact factor: 49.962
Authors: Joaquim Calbo; Erwin van Montfort; Natalie Proost; Ellen van Drunen; H Berna Beverloo; Ralph Meuwissen; Anton Berns Journal: Cancer Cell Date: 2011-02-15 Impact factor: 31.743
Authors: J T Poirier; Irina Dobromilskaya; Whei F Moriarty; Craig D Peacock; Christine L Hann; Charles M Rudin Journal: J Natl Cancer Inst Date: 2013-06-05 Impact factor: 13.506
Authors: Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar Journal: Transl Lung Cancer Res Date: 2018-02
Authors: Robert J Cardnell; Lerong Li; Triparna Sen; Rasha Bara; Pan Tong; Junya Fujimoto; Abbie S Ireland; Matthew R Guthrie; Sheila Bheddah; Upasana Banerjee; Nene N Kalu; You-Hong Fan; Scott J Dylla; Faye M Johnson; Ignacio I Wistuba; Trudy G Oliver; John V Heymach; Bonnie S Glisson; Jing Wang; Lauren A Byers Journal: Oncotarget Date: 2017-09-01
Authors: Yu-Han Huang; Olaf Klingbeil; Xue-Yan He; Xiaoli S Wu; Gayatri Arun; Bin Lu; Tim D D Somerville; Joseph P Milazzo; John E Wilkinson; Osama E Demerdash; David L Spector; Mikala Egeblad; Junwei Shi; Christopher R Vakoc Journal: Genes Dev Date: 2018-06-26 Impact factor: 12.890
Authors: Kaushal Asrani; Alba Fc Torres; Juhyung Woo; Thiago Vidotto; Harrison K Tsai; Jun Luo; Eva Corey; Brian Hanratty; Ilsa Coleman; Srinivasan Yegnasubramanian; Angelo M De Marzo; Peter S Nelson; Michael C Haffner; Tamara L Lotan Journal: J Pathol Date: 2021-09-23 Impact factor: 7.996
Authors: Joseph M Chan; Álvaro Quintanal-Villalonga; Vianne Ran Gao; Yubin Xie; Viola Allaj; Ojasvi Chaudhary; Ignas Masilionis; Jacklynn Egger; Andrew Chow; Thomas Walle; Marissa Mattar; Dig V K Yarlagadda; James L Wang; Fathema Uddin; Michael Offin; Metamia Ciampricotti; Besnik Qeriqi; Amber Bahr; Elisa de Stanchina; Umesh K Bhanot; W Victoria Lai; Matthew J Bott; David R Jones; Arvin Ruiz; Marina K Baine; Yanyun Li; Natasha Rekhtman; John T Poirier; Tal Nawy; Triparna Sen; Linas Mazutis; Travis J Hollmann; Dana Pe'er; Charles M Rudin Journal: Cancer Cell Date: 2021-10-14 Impact factor: 31.743
Authors: Demetra P Kelenis; Kathia E Rodarte; Rahul K Kollipara; Karine Pozo; Shreoshi Pal Choudhuri; Kyle B Spainhower; Sarah J Wait; Victor Stastny; Trudy G Oliver; Jane E Johnson Journal: Cancer Res Date: 2022-09-02 Impact factor: 13.312
Authors: Carl M Gay; C Allison Stewart; Elizabeth M Park; Lixia Diao; Sarah M Groves; Simon Heeke; Barzin Y Nabet; Junya Fujimoto; Luisa M Solis; Wei Lu; Yuanxin Xi; Robert J Cardnell; Qi Wang; Giulia Fabbri; Kasey R Cargill; Natalie I Vokes; Kavya Ramkumar; Bingnan Zhang; Carminia M Della Corte; Paul Robson; Stephen G Swisher; Jack A Roth; Bonnie S Glisson; David S Shames; Ignacio I Wistuba; Jing Wang; Vito Quaranta; John Minna; John V Heymach; Lauren Averett Byers Journal: Cancer Cell Date: 2021-01-21 Impact factor: 31.743